JAGX
MaterialsJaguar Health Inc
Live · NASDAQ · May 9, Close
What's Moving JAGX Today?
No stock-specific AI insight has been generated for JAGX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
JAGX News
20 articles- Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price RuleYahoo Finance·May 8, 2026
- Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)Yahoo Finance·May 6, 2026
- Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut HealthYahoo Finance·May 4, 2026
- Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in DogsYahoo Finance·Apr 29, 2026
- Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock SplitYahoo Finance·Apr 27, 2026
- Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)Yahoo Finance·Apr 24, 2026
- Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of StockholdersYahoo Finance·Apr 20, 2026
- Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) ProgramsYahoo Finance·Apr 13, 2026
- Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...Yahoo Finance·Apr 11, 2026
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company UpdatesYahoo Finance·Apr 10, 2026
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsYahoo Finance·Apr 8, 2026
- Jaguar Health Reports 2025 FinancialsYahoo Finance·Apr 7, 2026
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI CongressYahoo Finance·Apr 2, 2026
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)Yahoo Finance·Mar 18, 2026
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite SuppressionYahoo Finance·Mar 16, 2026
- Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingYahoo Finance·Mar 13, 2026
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term CatalystsYahoo Finance·Mar 11, 2026
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thYahoo Finance·Mar 10, 2026
- Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing WarrantsYahoo Finance·Mar 9, 2026
- Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1Yahoo Finance·Mar 3, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Jaguar Health Inc
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.